Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.

De Hert, Marc, Detraux, Johan, van Winkel, Ruud, Yu, Weiping, Correll, Christoph U.·2012·Nature Reviews Endocrinology

DOI 10.1038/nrendo.2011.156

Cited by (1,000)

Items 401–500 of 1,000

Differential Effects of Acute Treatment With Antipsychotic Drugs on Peripheral Catecholamines
Heidi N. Boyda, Amanzo A. Ho, Lurdes Tse, Ric M. Procyshyn, Jessica W. Y. Yuen, David D. Kim, William G. Honer, Alasdair M. Barr · 2020 · Frontiers in Psychiatry
The effect of brexpiprazole in adult outpatients with early-episode schizophrenia
ASHOK K. MALLA, Ai Ota, Kazuhiro Nagamizu, Pamela P. Perry, Emmanuelle Weiller, Ross A. Baker · 2016 · International Clinical Psychopharmacology
Mechanistic/mammalian target of rapamycin and side effects of antipsychotics: insights into mechanisms and implications for therapy
Chuanjun Zhuo, Yong Ji Xu, Weihong Hou, Jiayue Chen, Qianchen Li, Zhidong Liu, Guangqian Dou, Yun Sun, Ranli Li, Xiaoyan Ma et al. · 2022 · Translational Psychiatry
Effects of antipsychotics on heart rate in treatment of schizophrenia: a systematic review and meta-analysis
Maximilian Huhn, Thomas J. Arndt, Johannes Schneider‐Thoma, Stefan Leucht · 2022 · Therapeutic Advances in Psychopharmacology
The metabolic adverse effects of antipsychotic use in individuals with intellectual and/or developmental disability: A systematic review and meta‐analysis
Emily Smith, Nicolette Stogios, Emily Au, Kateryna Maksyutynska, Riddhita De, Andrew Ji, Mikkel Erlang Sørensen, Laura St. John, Hsiang‐Yuan Lin, Pushpal Desarkar et al. · 2022 · Acta Psychiatrica Scandinavica
Impact of low‐dose quetiapine‐use on glycosylated hemoglobin, triglyceride and cholesterol levels
Mikkel Højlund, Henrik Støvring, Kjeld Andersen, Christoph Ulrich Correll, Jesper Hallas · 2022 · Acta Psychiatrica Scandinavica
Glucometabolic Hormones and Cardiovascular Risk Markers in Antipsychotic-Treated Patients
Bjørn Hylsebeck Ebdrup, Filip Krag Knop, Anna Madsen, Henrik Bindesbøl Mortensen, Birgitte Søgaard, Jens Juul Holst, Pal Bela Szecsi, Henrik Lublin · 2014 · The Journal of Clinical Psychiatry
Psychosis and cardiovascular disease: Is diet the missing link?
Marni Anne Nenke, Lisa Anne Hahn, Campbell Henry Thompson, Dennis Liu, Cherrie Ann Galletly · 2015 · Schizophrenia Research
Incident somatic comorbidity after psychosis: results from a retrospective cohort study based on Flemish general practice data
Carla Truyers, Frank Buntinx, Jan De Lepeleire, Marc D. Binder, Ruud van Winkel, Bert Aertgeerts, Stefaan Bartholomeeusen, Emmanuel M. E. H. Lesaffre · 2011 · BMC Family Practice
Brain volume change in first‐episode psychosis: an effect of antipsychotic medication independent of BMI change
Kjetil Nordbø Jørgensen, Ragnar Nesvåg, Stener Nerland, Lynn Egeland Mørch-Johnsen, Lars Tjelta Westlye, Elisabeth Heffermehl Lange, Unn Kristin Haukvik, Cecilie Bhandari Hartberg, Ingrid S. Melle, Ole A. Andreassen et al. · 2016 · Acta Psychiatrica Scandinavica
Reverse Integration Initiatives for Individuals With Serious Mental Illness
Martha C. Ward, Benjamin G. Druss · 2017 · FOCUS The Journal of Lifelong Learning in Psychiatry
A Practical Approach to Avoiding Cardiovascular Adverse Effects of Psychoactive Medications
Judith Brouillette, Stanley Nattel · 2017 · Canadian Journal of Cardiology
Synthesis and biological evaluation of a series of multi-target N-substituted cyclic imide derivatives with potential antipsychotic effect
Mingshuo Xu, Yu Wang, Feipu Yang, Chunhui Wu, Zhen Wang, Bin Ye, Xiangrui Jiang, Qingjie Zhao, Jianfeng Li, Yongjian Liu et al. · 2018 · European Journal of Medicinal Chemistry
Age Impacts Olanzapine Exposure Differently During Use of Oral Versus Long-Acting Injectable Formulations
Marit Tveito, Robert L. Smith, Espen Molden, Tore Haslemo, Helge Refsum, Cecilie Bhandari Hartberg, Christoph Ulrich Correll, Gudrun Høiseth · 2018 · Journal of Clinical Psychopharmacology
Investigating the Agreement Between Cardiovascular Disease Risk Calculators Among People Diagnosed With Schizophrenia
Alexandra Berry, Richard Drake, Roger Thomas Webb, Darren Mark Ashcroft, Matthew Carr, Alison Ruth Yung · 2018 · Frontiers in Psychiatry
SURVIVE: let the dead help the living—an autopsy-based cohort study for mapping risk markers of death among those with severe mental illnesses
Jytte Banner, Christian Bjerre Høyer, Martin Roest Christensen, Alexandra Gheorghe, Anne Birgitte Dyhre Bugge, Gyda Lolk Ottesen, Lene Warner Thorup Boel, Jørgen Lange Thomsen, Line Kruckow, Christina Jacobsen · 2018 · Scandinavian Journal of Forensic Science
Metabolic Monitoring Rates of Youth Treated with Second-Generation Antipsychotics in Usual Care: Results of a Large US National Commercial Health Plan
Jennifer Hayden, Libby Horter, Taft Parsons, Matthew W. Ruble, Sabrina Townsend, Christina C. Klein, Rodrigo Patino Duran, Jeffrey A. Welge, Stephen Crystal, Nick C. Patel et al. · 2019 · Journal of Child and Adolescent Psychopharmacology
An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder
Leslie Citrome, Christine E. Graham, Adam Simmons, Ying Jiang, Mark S. Todtenkopf, Bernard L. Silverman, Lauren DiPetrillo, Hannah Cummings, Lei Sun, David McDonnell · 2021 · Neuropsychiatric Disease and Treatment
The impact of binge eating behavior on lithium- and quetiapine-associated changes in body weight, body mass index, and waist circumference during 6 months of treatment: Findings from the bipolar CHOICE study
Satyanarayana R. Yaramala, Susan L. McElroy, Jennifer R. Geske, Stacey J. Winham, Keming Gao, Noreen A. Reilly-Harrington, Terence A. Ketter, Thilo Deckersbach, Gustavo Kinrys, Masoud Kamali et al. · 2018 · Journal of Affective Disorders
Comparing Tolerability of Olanzapine in Schizophrenia and Affective Disorders:
Ross J. Baldessarini · 2012 · Drug Safety
Evaluating Monitoring Guidelines of Clozapine-Induced Adverse Effects: a Systematic Review
Sarah Smessaert, Johan Detraux, Siska Desplenter, Marc D. Binder · 2024 · CNS Drugs
Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia
H. Taipale, A. Tanskanen, J. Luykx, Marco Solmi, S. Leucht, C. Correll, J. Tiihonen · 2022 · Schizophrenia bulletin
Metabolic syndrome and cardiovascular risk between clozapine and non-clozapine antipsychotic users with schizophrenia
Yue Feng Quek, Yuen Mei See, Jie Yin Yee, Gurpreet Rekhi, Boon Tat Ng, Charmaine Yu Zheng Tang, Jimmy Lee · 2022 · Asian Journal of Psychiatry
Lipid Biomarker Research in Bipolar Disorder: A Scoping Review of Trends, Challenges, and Future Directions
John Kim Hiller, Andreas Jangmo, Martin Tesli, Piotr Pawel Jaholkowski, Eva Zsuzsanna Hoseth, Nils Eiel Steen, Marit Haram · 2023 · Biological Psychiatry Global Open Science
Knowledge of Psychiatric Nurses About the Potentially Lethal Side-Effects of Clozapine
Marc D. Binder, Annelien De Beugher, Kim Sweers, Martien Wampers, Christoph Ulrich Correll, Dan Cohen · 2015 · Archives of Psychiatric Nursing
Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis
Hoda Moteshafi, Émmanuel Stip · 2012 · Expert Opinion on Drug Safety
Altered gene expression in antipsychotic-induced weight gain
Benedicto Crespo‐Facorro, Carlos Prieto, Jesús Sainz · 2019 · Schizophrenia
Chapter 12 – Type 2 Diabetes Mellitus
D. Vancampfort, Richard I. G. Holt, B. Stubbs, M. de Hert, K. Samaras, A. Mitchell · 2016 · Elsevier eBooks
Determinants of Physical Health Self-Management Behaviours in Adults With Serious Mental Illness: A Systematic Review
Peter A Coventry, Ben Young, Abisola Balogun, Jo Taylor, Jennifer Valeska Elli Brown, Charlotte Emma Wray Kitchen, Ian Kellar, Emily Jane Peckham, Sue Bellass, Judy M Wright et al. · 2021 · Frontiers in Psychiatry
Safety Profile of Antipsychotic Drugs: Analysis Based on a Provincial Spontaneous Reporting Systems Database
Kangyuan Guo, Zhanchun Feng, Shanquan Chen, Ziqi Yan, Zhiming Jiao, Da Feng · 2022 · Frontiers in Pharmacology
Weight Gain and its Correlates among Forensic Inpatients
N. Zoe Hilton, Elke Ham, Carol Lang, Grant T. Harris · 2015 · The Canadian Journal of Psychiatry
T4 and waist:hip ratio as biomarkers of antipsychotic-induced weight gain in Han Chinese inpatients with schizophrenia
Shen Li, Ying Gao, Hao Lv, Miaomiao Zhang, Lili Wang, Rui Jiang, Chengai Xu, Xueshi Wang, Ming Gao, Yukun He et al. · 2017 · Psychoneuroendocrinology
Association of Low-Dose Quetiapine and Diabetes
Mikkel Højlund, Lars Christian Lund, Kjeld Andersen, Christoph Ulrich Correll, Jesper Hallas · 2021 · JAMA Network Open
Comparison of mental-physical comorbidity, risk of death and mortality among patients with mental disorders — A retrospective cohort study
Xiao Wei Tan, Eng Sing Lee, Matthias Paul Han Sim Toh, Alvin Lum, Ee-Jin Darren Seah, Khai Pang Leong, Christopher Yi Wen Chan, Daniel S S Fung, Phern Chern Tor · 2021 · Journal of Psychiatric Research
The Development of a Nutrition Screening Tool for Mental Health Settings Prone to Obesity and Cardiometabolic Complications: Study Protocol for the NutriMental Screener
Scott B. Teasdale, Sabrina Mörkl, Sonja Mötteli, Annabel Sandra Mueller‐Stierlin · 2021 · International Journal of Environmental Research and Public Health
The role of NLRP3 inflammasome in psychotropic drug-induced hepatotoxicity
Wenqing Mu, Guang Xu, Ziying Wei, Zhilei Wang, Qin Qin, Lin Li, Lutong Ren, Tingting Liu, Zhie Fang, Yan Yang et al. · 2022 · Cell Death Discovery
The Association Between Antipsychotics and Weight Gain and the Potential Role of Metformin Concomitant Use: A Retrospective Cohort Study
Alqassem Y. Hakami, Razaz Abdulaziz Felemban, Rami Ghazi Ahmad, Abdulrahman Hamid Alsamadani, Hassan K. Salamatullah, Jamil M Baljoon, Loay J Alghamdi, Mostafa H. Ramadani Sindi, Mohamed Eldigire Ahmed · 2022 · Frontiers in Psychiatry
Drug–drug interactions involving combinations of antipsychotic agents with antidiabetic, lipid-lowering, and weight loss drugs
A Buzea, Peter Manu, Lorena Dima, Christoph Ulrich Correll · 2022 · Expert Opinion on Drug Metabolism & Toxicology
Atypical Antipsychotics Olanzapine, Quetiapine, and Risperidone and Risk of Acute Major Cardiovascular Events in Young and Middle-Aged Adults: A Nationwide Register-Based Cohort Study in Denmark
Björn Pasternak, Henrik Svanström, Mattis Flyvholm Ranthe, Mads Melbye, Anders Peter Hviid · 2014 · CNS Drugs
Patients reasons for obtaining psychotropic medications without a prescription at retail pharmacies in Central Saudi Arabia
Fahad Dakheel Alosaimi, Fay S. Alruwais, Fadah A. Alanazi, Ghaida A. Alabidi, Nadia Aljomah, Nuha Saleh Al-Salameh · 2016 · Neurosciences
Impact of histamine receptors H1 and H3 polymorphisms on antipsychotic-induced weight gain
Arun Kumar Tiwari, Danning Zhang, Jennie G. Pouget, Clement C.H. Zai, Nabilah I. Chowdhury, Eva J. Brandl, Qin Li, Natalie Freeman, Jeffrey Alan Lieberman, Herbert Y. Meltzer et al. · 2016 · The World Journal of Biological Psychiatry
The Effect of Antipsychotics on Bone Mineral Density and Sex Hormones in Male Patients with Schizophrenia.
Süheyla Doğan Bulut, Serdar Bulut, Dicle Görkem Atalan, Rıza Gökçer Tulacı, Türker Türker, Eda Gürçay, Çiğdem Aydemir · 2016 · PubMed
Physical health policies and metabolic screening in mental health care systems of sub-Saharan African countries: a systematic review
James Mugisha, Marc D. Binder, Brendon Stubbs, David Basangwa, Davy Vancampfort · 2017 · International Journal of Mental Health Systems
Genetic polymorphisms of HTR2C, LEP and LEPR on metabolic syndromes in patients treated with atypical antipsychotic drugs
Apichaya Puangpetch, Weerapon Unaharassamee, Napa Jiratjintana, Napatrupron Koomdee, Chonlaphat Sukasem · 2018 · Journal of Pharmacy and Pharmacology
The Influence of Metabolic Syndrome and Sex on the DNA Methylome in Schizophrenia
Kyle Jon Burghardt, Jaclyn M. Goodrich, Brittany N. Lines, Vicki L. Ellingrod · 2018 · International Journal of Genomics
Subtle Modifications to the Indole-2-carboxamide Motif of the Negative Allosteric ModulatorN-((trans)-4-(2-(7-Cyano-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)-1H-indole-2-carboxamide (SB269652) Yield Dramatic Changes in Pharmacological Activity at the Dopamine D2Receptor
Anitha Kopinathan, Christopher J. Draper-Joyce, Mónika Szabó, Arthur Christopoulos, Peter J. Scammells, J. Robert Lane, Ben Capuano · 2018 · Journal of Medicinal Chemistry
Integrative network analysis identifies differential regulation of neuroimmune system in Schizophrenia and Bipolar disorder
Ankur Sahu, Hussain Ahmed Chowdhury, Mithil Gaikwad, Chen Chongtham, Uddip Talukdar, Jadab Kishore Phukan, Dhruba K. Bhattacharyya, Pankaj Barah · 2019 · Brain Behavior & Immunity - Health
Schizophrenia patients with a metabolically abnormal obese phenotype have milder negative symptoms
Juan Wang, Yulong Zhang, Zhiwei Liu, Yating Yang, Yi Zhong, Xiaoshuai Ning, Yelei Zhang, Tongtong Zhao, Lei Xia, Feng Geng et al. · 2020 · BMC Psychiatry
Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial
J. Larsen, Louise Vedtofte, J. Holst, P. Oturai, A. Kjær, Christoph U Corell, T. Vilsbøll, A. Fink-Jensen · 2014 · BMJ Open
The physical health of people with schizophrenia in Asia: Baseline findings from a physical health check programme.
S. Thongsai, R. Gray, D. Bressington · 2016 · Journal of Psychiatric and Mental Health Nursing
Diabetes Risk Potentially Underestimated in Youth and Children Receiving Antipsychotics
Katherine Samaras, Christoph Ulrich Correll, Alex J. Mitchell, Marc D. Binder · 2014 · JAMA Psychiatry
Primary prevention of cardiovascular events in patients with major mental illness: a possible role for statins
Andrade, Chittaranjan · 2013 · Bipolar Disorders
Possible associations between antioxidant enzyme polymorphisms and metabolic abnormalities in patients with schizophrenia
Junji Saruwatari, Norio Yasui‐Furukori, Ryoko Kamihashi, Yuki Yoshimori, Kentaro Oniki, Shoko Tsuchimine, Madoka Noai, Yasushi Sato, Taku Nakagami, Norio Sugawara et al. · 2013 · Neuropsychiatric Disease and Treatment
Prescribing Patterns of Psychotropic Drugs and Risk of Violent Behavior: A Prospective, Multicenter Study in Italy
Ester di Giacomo, Alberto Stefana, Valentina Candini, Giorgio Bianconi, Luisa Canal, Massimo Clerici, Giovanni Lo Conte, Maria Teresa Ferla, Laura Iozzino, Giulio Sbravati et al. · 2020 · The International Journal of Neuropsychopharmacology
Metabolic side effects of antipsychotic drugs in individuals with schizophrenia during medium- to long-term treatment: protocol for a systematic review and network meta-analysis of randomized controlled trials
Johannes Schneider‐Thoma, Angelika Kapfhammer, Dongfang Wang, Irene Bighelli, Spyridon Siafis, Hui Wu, Wulf‐Peter Hansen, John M. Davis, Georgia Salanti, Stefan Leucht · 2021 · Systematic Reviews
Drugs Interfering with Insulin Resistance and Their Influence on the Associated Hypermetabolic State in Severe Burns: A Narrative Review
Maria Greabu, Silviu Constantin Bădoiu, Iulia-Ioana Stănescu-Spînu, Daniela Miricescu, Alexandra Totan, Silvia Elena Badoiu, Michel Costagliola, Viorel Jinga · 2021 · International Journal of Molecular Sciences
Association of antipsychotic use with breast cancer: a systematic review and meta-analysis of observational studies with over 2 million individuals
Janice Ching Nam Leung, Dora Wai Yee Ng, Rachel Yui Ki Chu, Edward Wai Wa Chan, Lei Huang, Dawn Hei Lum, Esther W. Chan, Daniel J. Smıth, Ian Chi Kei Wong, Francisco Tsz Tsun Lai · 2022 · Epidemiology and Psychiatric Sciences
Identification of four novel loci associated with psychotropic drug-induced weight gain in a Swiss psychiatric longitudinal study: A GWAS analysis
Jennifer Sjaarda, Aurélie Delacrétaz, Céline Dubath, Nermine Laaboub, Marianna Piras, Claire Grosu, Frederik Vandenberghe, Séverine Crettol, Nicolas Ansermot, Franziska Gamma et al. · 2023 · Molecular Psychiatry
The metabolic syndrome in untreated schizophrenia patients: prevalence and putative mechanisms.
Snigdha Mettu Reddy, Calum T Goudie, Mark A Agius · 2013 · PubMed
Dopamine D2 Receptor Signaling in the Nucleus Accumbens Comprises a Metabolic–Cognitive Brain Interface Regulating Metabolic Components of Glucose Reinforcement
Michael Michaelides, Michael L Miller, Jennifer A. DiNieri, Juan L. Gomez, Elizabeth K. C. Schwartz, Gabor Egervári, Gene Jack Wang, Charles V. Mobbs, Nora D. Volkow, Yasmin L. Hurd · 2017 · Neuropsychopharmacology
Sex differences in gene expression related to antipsychotic induced weight gain
Jesús Sainz, Carlos Alberto Vanegas Prieto, Benedicto Crespo‐Facorro · 2019 · PLoS ONE
Routine screening and rates of metabolic syndrome in patients treated with clozapine and long-acting injectable antipsychotic medications: a cross-sectional study
A. Lydon, J. Vallely, Ailbhe Tummon, Senan Maher, S. Sabri, J. McLoughlin, Aaron Liew, Colm McDonald, Brian P. Hallahan · 2020 · Irish Journal of Psychological Medicine
Influence of MCHR2 and MCHR2-AS1 Genetic Polymorphisms on Body Mass Index in Psychiatric Patients and In Population-Based Subjects with Present or Past Atypical Depression
Aurélie Delacrétaz, Martin Preisig, Frederik Vandenberghe, Núria Saigí-Morgui, Lina Quteineh, Eva Choong, Mehdi Gholam‐Rezaee, Zoltán Kutalik, Pierre Julius Magistretti, Jean‐Michel Aubry et al. · 2015 · PLoS ONE
The regulatory effects of second-generation antipsychotics on lipid metabolism: potential mechanisms mediated by the gut microbiota and therapeutic implications
Chen, Hui, Cao, Ting, Zhang, Bikui, Cai, Hualin · 2023 · Frontiers in Pharmacology
Association of serum lipid levels with psychotic symptoms in first-episode and drug naïve outpatients with major depressive disorder: a large-scale cross-sectional study
Xiaohong Wang, Liying Yang, Jiacheng Liu, Chuanyi Kang, Yue Zheng, Siyu Qiu, Ying Y. Zhao, Colin Goodman, Hanjing Emily Wu, Na Zhao et al. · 2021 · Journal of Affective Disorders
Insulin and glucose metabolism with olanzapine and a combination of olanzapine and samidorphan: exploratory phase 1 results in healthy volunteers
Frederico G. S. Toledo, William F. Martin, Linda Morrow, Carine Beysen, Daiva R. Bajorunas, Ying Jiang, Bernard L. Silverman, David McDonnell, Mark Namchuk, John W. Newcomer et al. · 2021 · Neuropsychopharmacology
Association between olanzapine concentration and metabolic dysfunction in drug-naive and chronic patients: similarities and differences
Dongyu Kang, Jinjun Lu, Wenqing Liu, Ping Shao, Renrong Wu · 2022 · Schizophrenia
A Complex Combination Therapy for a Complex Disease–Neuroimaging Evidence for the Effect of Music Therapy in Schizophrenia
Elena Ivanova, Tzvetina Panayotova, Ivan Grechenliev, Bogomil Peshev, Penka Y Kolchakova, Vihra Krumova Milanova · 2022 · Frontiers in Psychiatry
Drug–drug interactions involving antipsychotics and antihypertensives
A Buzea, Lorena Dima, Christoph Ulrich Correll, Peter Manu · 2022 · Expert Opinion on Drug Metabolism & Toxicology
Metabolic Side Effects and Pharmacogenetics of Second-Generation Antipsychotics in Children
Angela M. Devlin, Constadina Panagiotopoulos · 2015 · Pharmacogenomics
Dual Modulation of Human P-Glycoprotein and ABCG2 with Prodrug Dimers of the Atypical Antipsychotic Agent Paliperidone in a Model of the Blood–Brain Barrier
Kelsey C. Bohn, Allison Lange, Jean A. Chmielewski, Christine A. Hrycyna · 2017 · Molecular Pharmaceutics
The safety and tolerability of aripiprazole once-monthly as maintenance treatment for bipolar I disorder: A double-blind, placebo-controlled, randomized withdrawal study
Joseph R. Calabrese, Raymond Sanchez, Na Jin, Joan C. Amatniek, Kevin Cox, Brian R. Johnson, Pamela P. Perry, Peter Hertel, Pedro Such, Robert D. McQuade et al. · 2018 · Journal of Affective Disorders
The use of antipsychotics in preschoolers: A veto or a sensible last option?
Jessica Memarzia, Derek Kenneth Tracy, Giovanni Giaroli · 2014 · Journal of Psychopharmacology
Leukocyte telomere length in Hispanic schizophrenia patients under treatment with olanzapine
Nancy Monroy‐Jaramillo, Yaneth Rodríguez‐Agudelo, Luis Carlos Aviña-Cervantes, David Leland Roberts, Dawn I. Velligan, Consuelo Walss‐Bass · 2017 · Journal of Psychiatric Research
The effect of metilpheniydate, risperidone and combination therapy on ECG in children with attention-deficit hyperactivity disorder
Derya Karpuz, Olgu Hallıoğlu, Fevziye Toros, Bahar Taşdelen · 2017 · Journal of Electrocardiology
The Urgent Need for Optimal Monitoring of Metabolic Adverse Effects in Children and Youngsters Who Take On-label or Off-label Antipsychotic Medication
Marc D. Binder, Johan Detraux · 2018 · JAMA Psychiatry
The prevalence and risk factors of the metabolic syndrome in inpatients with intellectual disability
B. Room, Olaf Timmermans, Pieternella Roodbol · 2016 · Journal of Intellectual Disability Research
Antioxidant Enzymes and Weight Gain in Drug-naive First-episode Schizophrenia Patients Treated with Risperidone for 12 Weeks: A Prospective Longitudinal Study
Haixia Liu, Rui Yu, Yanan Gao, Xirong Li, Xiaoni Guan, Thomas R. Kosten, Meihong Xiu, Xiangyang Zhang · 2021 · Current Neuropharmacology
Increased Metabolic Potential, Efficacy, and Safety of Emerging Treatments in Schizophrenia
Jonathan M. Meyer, Christoph Ulrich Correll · 2023 · CNS Drugs
Mental Health Staff’s Perspectives on Tapering of Antipsychotic Medication: A Focus Group Study
Kickan Roed, Niels Buus, Jimmi Nielsen, Puk S. Christensen, Julie Midtgaard · 2023 · Qualitative Health Research
Being more satisfied with romantic relationship status is associated with increased mental wellbeing in people with experience of psychosis
Rebecca White, Gillian Haddock, Maria Haarmans, Filippo Varese · 2023 · Frontiers in Psychiatry
Comparative predictive efficacy of atherogenic indices on metabolic syndrome in patients with schizophrenia
Yu-Tung Tien, Liang‐Jen Wang, Yu Lee, Pao‐Yen Lin, Chi‐Fa Hung, Mian‐Yoon Chong, Yu‐Chi Huang · 2023 · Schizophrenia Research
Management of antipsychotics in primary care: Insights from healthcare professionals and policy makers in the United Kingdom
Alan Woodall, Aseel S. Abuzour, Samantha A. Wilson, Frances S Mair, Iain Edward Buchan, Sally B. Sheard, Paul Atkinson, Dan W. Joyce, Pyers Symon, Lauren E. Walker · 2024 · PLoS ONE
Importance of good hosting: reviewing the bi-directionality of the microbiome-gut-brain-axis
Carolina F. F. A. Costa, Joana Ferreira‐Gomes, Fernando Barbosa, Benedita Sampaio‐Maia, Philip W. J. Burnet · 2024 · Frontiers in Neuroscience
Relevance of diet in schizophrenia: a review focusing on prenatal nutritional deficiency, obesity, oxidative stress and inflammation
Viorica Rarinca, Amalia Vasile, Mălina Visternicu, Vasile Burlui, Gabriela Halitchi, Alin Stelian Ciobica, Ana-Maria Sîngeap, Romeo Dobrin, Ecaterina Burlui, Lucian Maftei et al. · 2024 · Frontiers in Nutrition
Quality of physical health care among patients with personality disorder
Rahil Sanatinia, Sophie Middleton, Tint Lin, Oliver Dale, Mike Crawford · 2015 · Personality and Mental Health
Bridging the gap from evidence to policy and practice: Reducing the progression to metabolic syndrome for children and adolescents on antipsychotic medication
Valsamma Eapen, David Shiers, Jackie Curtis · 2012 · Australian & New Zealand Journal of Psychiatry
Antipsychotics for acute schizophrenia: making choices
Christoph Ulrich Correll, Marc D. Binder · 2013 · The Lancet
Missing laboratory results data in electronic health databases: implications for monitoring diabetes risk
James Flory, Jason A. Roy, Joshua J. Gagne, Kevin Haynes, Lisa J. Herrinton, Christine Y. Lu, Elisabetta Patorno, Azadeh Shoaibi, Marsha A. Raebel · 2016 · Journal of Comparative Effectiveness Research
Who needs antipsychotic maintenance treatment and who does not? Our need to profile and personalize the treatment of first episode psychosis
Lex Wunderink · 2017 · Schizophrenia Research
Second-Generation Antipsychotics in Adolescent Psychiatric Patients: Metabolic Effects and Impact of an Early Weight Change to Predict Longer Term Weight Gain
Frederik Vandenberghe, Alexandra Najar-Giroud, Laurent Holzer, Philippe Conus, Chin B. Eap, Anne‐Emmanuelle Ambresin · 2018 · Journal of Child and Adolescent Psychopharmacology
Early treatment resistance in a Latin-American cohort of patients with schizophrenia
Cristián Mena, Alfonso González‐Valderrama, Bárbara Iruretagoyena, Juan Pablo Undurraga, Nicolas Andres Crossley · 2018 · Schizophrenia Research
Clinical Characteristics of Patients With Schizophrenia Who Successfully Discontinued Antipsychotics
Hideaki Tani, Takefumi Suzuki, W. Wolfgang Fleischhacker, Masayuki Tomita, Masaru Mimura, Hiroyuki Uchida · 2018 · Journal of Clinical Psychopharmacology
Susceptibility of male wild type mouse strains to antipsychotic-induced weight gain
Rizaldy C. Zapata, Olivia Osborn · 2020 · Physiology & Behavior
Traditional Chinese herbal medicine in treating amenorrhea caused by antipsychotic drugs: Meta-analysis and systematic review
Liangshuai Liu, Heping Li, Guosheng Tan, Zhenjiang Ma · 2022 · Journal of Ethnopharmacology
Short-term efficacy and safety of lurasidone versus placebo in antipsychotic-naïve versus previously treated adolescents with an acute exacerbation of schizophrenia
Christoph Ulrich Correll, Michael Tocco, Jay Hsu, ROBERT S. GOLDMAN, Andrei Pikalov · 2022 · European Psychiatry
Dopamine partial agonists: a discrete class of antipsychotics
David M. Taylor, Ramalingam N Chithiramohan, Jasdev Grewal, Avirup Gupta, Lars Koch Hansen, Gavin P. Reynolds, Sofia Pappa · 2022 · International Journal of Psychiatry in Clinical Practice
Is Clozapine-induced Weight Gain Dose-dependent? Results From a Prospective Cohort Study
Marianna Piras, Jihane Chahma, Setareh Ranjbar, Nermine Laaboub, Claire Grosu, Kerstin Jessica Plessen, Armin von Gunten, Philippe Conus, Chin B. Eap · 2023 · Schizophrenia Bulletin
The effects of antipsychotic switching on diabetes in chronic schizophrenia
Rosanna Arnoldy, Jackie Curtis, Katherine Samaras · 2013 · Diabetic Medicine
Metabolic syndrome in first‐time hospitalized patients with depression: a 1‐year follow‐up study
Lene Nyboe, Claus Høstrup Vestergaard, Hans Lund, M. K. Møller, Poul Videbech · 2015 · Acta Psychiatrica Scandinavica